HECTD2

Across TCGA pan-cancer cohorts, HECTD2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated HECTD2 data layer compared with 6 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher HECTD2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated HECTD2 expression acts as an unfavorable survival marker, although some lineages such as UCS and BRCA show a favorable association.

STAD, ACC, and LIHC are the cancer types where HECTD2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.241	0.521	.002	77	view →
ACC	OS	Median	All	0.396	0.803	<.001	69	view →
LIHC	OS	Median	All	0.706	0.843	<.001	50	view →
UVM	DFS	Quartile	III,IV	0.183	0.848	<.001	47	view →
UCS	DFS	Median	IV	0.952	0.367	.001	40	view →
BRCA	DFS	Median	III,IV	0.942	0.807	<.001	35	view →
KIRP	DFS	Tertile	II,III,IV	0.353	0.769	.002	33	view →
KICH	OS	Median	II,III,IV	0.757	1.000	.005	30	view →
PAAD	OS	Median	All	0.483	0.292	.007	13	view →
THYM	DFS	Tertile	III,IV	1.000	0.419	.012	11	view →
SARC	DFS	Quartile	All	0.419	0.673	.012	9	view →
ESCA	OS	Tertile	III,IV	0.602	0.328	.030	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

HECTD2–STAD (OS)

Open the STAD breakdown →